EBA
HRTX icon

Eagle Bay Advisors’s Heron Therapeutics HRTX Stock Holding History

Eagle Bay Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-193
Closed -$295 – 497
2024
Q4 		$295 Hold
193
– – ﹤0.01% 977
2024
Q3 		$384 Hold
193
– – ﹤0.01% 1319
2024
Q2 		$676 Hold
193
– – ﹤0.01% 951
2024
Q1 		$535 Hold
193
– – ﹤0.01% 943
2023
Q4 		$328 Hold
193
– – ﹤0.01% 807
2023
Q3 		$199 Hold
193
– – ﹤0.01% 831
2023
Q2 		$224 Hold
193
– – ﹤0.01% 822
2023
Q1 		$291 Hold
193
– – ﹤0.01% 888
2022
Q4 		$483 Hold
193
– – ﹤0.01% 885
2022
Q3 		$1K Hold
193
– – ﹤0.01% 832
2022
Q2 		$538 Buy
+193
New +$775 ﹤0.01% 992
2022
Q1 		– Sell
-193
Closed -$2K – 592
2021
Q4 		$2K Hold
193
– – ﹤0.01% 914
2021
Q3 		$2K Hold
193
– – ﹤0.01% 948
2021
Q2 		$3K Buy
+193
New +$3.07K ﹤0.01% 795

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eagle Bay Advisors's HRTX Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Heron Therapeutics (HRTX) in Q1 2025, closing a stake of 193 shares — an estimated $295 sold.

Eagle Bay Advisors first reported a position in HRTX in Q2 2021 and held it in 14 quarters. The position peaked at $3K in Q2 2021. 164 funds tracked by Wall St. Rank hold HRTX as of Q1 2025.

  • Eagle Bay Advisors reported no remaining Heron Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Eagle Bay Advisors sold 193 Heron Therapeutics shares in Q1 2025, an estimated $295.
  • Eagle Bay Advisors first reported a position in Heron Therapeutics in Q2 2021 and held it in 14 quarters.
  • Eagle Bay Advisors's Heron Therapeutics position peaked at $3K in Q2 2021.
  • 164 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.